Schrödinger: Software Recurring Revenue Makes Drug Creation the Product
Schr f6dinger (SDGR) is a two-legged company: established software sales that generate recurring, high-margin revenue and an increasingly credible drug-discovery engine. With a $2.11B market cap, improving technical momentum and a large biosimulation market tailwind, SDGR is a constructive mid-term trade. Entry at $28.17, stop $22.00, target $36.00…